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Abstract
The normal function of Syk in epithelium of the developing or adult breast is not known, however, Syk suppresses tumor
growth, invasion, and metastasis in breast cancer cells. Here, we demonstrate that in the mouse mammary gland, loss of
one Syk allele profoundly increases proliferation and ductal branching and invasion of epithelial cells through the mammary
fat pad during puberty. Mammary carcinomas develop by one year. Syk also suppresses proliferation and invasion in vitro.
siRNA or shRNA knockdown of Syk in MCF10A breast epithelial cells dramatically increased proliferation, anchorage
independent growth, cellular motility, and invasion, with formation of functional, extracellular matrix-degrading
invadopodia. Morphological and gene microarray analysis following Syk knockdown revealed a loss of luminal and
differentiated epithelial features with epithelial to mesenchymal transition and a gain in invadopodial cell surface markers
CD44, CD49F, and MMP14. These results support the role of Syk in limiting proliferation and invasion of epithelial cells
during normal morphogenesis, and emphasize the critical role of Syk as a tumor suppressor for breast cancer. The question
of breast cancer risk following systemic anti-Syk therapy is raised since only partial loss of Syk was sufficient to induce
mammary carcinomas.
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Introduction
Understanding the normal function of Syk in the developing
and adult breast, its upstream activators and downstream effectors,
and epigenetic and genetic factors that cause its loss are vital for
breast cancer prognosis, prediction and treatment. However, Syk
plays an integral role in immune cell development and activation
and it has been identified as a drug target for autoimmune disease,
allergy and asthma. Syk is a tumor suppressor in breast cancer and
may well also be in gastric cancer and melanoma, although it may
be a tumor promoter in some invasive head and neck cancers and
certain lymphomas [for review, [1] and [2,3]]. A complete
understanding of the role of Syk as a tumor suppressor is vital for
assessing breast cancer risk in patients who might be candidates for
therapeutic suppression of Syk to control immune-related disease.
Syk mRNA is increasingly lost from normal adjacent to
hyperplastic to ductal carcinoma in situ (DCIS) to invasive tumors
compared with normal, disease free breast epithelium [4]. The
gene is hypermethylated in invasive breast cancer and loss of Syk
has been tied to poor outcome in breast cancer [for review, [1]].
Functional studies in nude mice and in vitro illustrate the role of Syk
in suppressing motility, invasion, and metastasis [1,5]. Syk has
been shown to block breast cancer cell migration and chemoinva-
sion via mechanisms involving down regulation of secreted growth
factor GRO-1 [6] and suppression of NF-kB, PI3K [7], Src [4],
and EGFR signaling pathways [8] [see also for review, [1]].
Studies on the role of Syk in cancer to date have all been
conducted using tumor cell lines with reintroduction of Syk into
highly invasive Syk negative cell lines or interference with
endogenous Syk in otherwise non-invasive tumor cells. However,
the normal function of Syk in mammary epithelium has not been
addressed, nor have experiments been performed to determine the
consequences of Syk loss from normal epithelial cells. MCF10A
immortalized breast epithelial cells and cells derived from them
serve as an in vitro model system to understand normal epithelial
function and development [9,10]. MCF10A, MCF10AneoT, and
DCIS.com form a series with which to model early cancer
progression [11]. MCF10A are Syk positive, but the Syk status or
functionality in this progression series is not known. The mouse
mammary gland is another system to model normal epithelial
behavior. The branching network of epithelial ducts arises from
the combination of proliferation and epithelial ductal invasion
through the fat pad via the formation of terminal end buds (TEB),
TEB bifurcation and lateral branching, and ductal elongation.
Unfortunately, nothing is known concerning Syk function in the
adult or developing breast. Syk knockout mice have been
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perinatal lethal, due to failure of lymphatic and blood vessels to
properly separate [14]. Other aspects of development such as
formation of mammary gland were not reported. Here we
determine the role of Syk in normal epithelium using these in
vitro and in vivo models. Taken together our results are consistent
with a critical role for Syk in blocking pre-neoplastic cell
proliferation and invasion and suggest that Syk does so by
affecting several major signaling pathways important for normal
breast development and maintenance.
Results
In vitro studies
Knockdown of Syk induces increased migration and cell
proliferation in human breast epithelial cells. First, we
investigated whether Syk loss in normal human breast epithelial
cells would have an impact on the ability of these cells to
proliferate and invade. For these studies, we utilized non-
transformed, immortalized MCF10A human breast epithelial
cells (MCF10A1) and two cell lines derived from them,
MCF10AneoT, and MCF10DCIS.com (DCIS.com), with
characteristics of normal, hyperplastic, and ductal carcinoma in
situ (DCIS), respectively. MCF10A contained the greatest amount
of Syk and MCF10AneoT and DCIS.com each had progressively
less (Figure 1A). Syk siRNA treatment effectively lowered Syk
protein levels up to 90% in all three cell lines (Figure 1A). Analysis
of cell proliferation and growth revealed that loss of Syk in each
cell line led to enhanced cell proliferation, approximately 4-fold
greater in MCF10A cells, 2 fold greater in MCF10AneoT, and 0.4
greater in DCIS.com (Figures 1B and 1C).
Next, we asked whether normal cells or the transformed
MCF10A derivatives migrated more efficiently following Syk
knockdown using a scratch/wound assay. Cell velocities and rate
of gap closure of the monolayer were significantly increased in
each cell line following Syk siRNA knockdown (Figures 1D and
Figure 1. Cell proliferation and migration of MCF10A, MCF10AneoT, and DCIS.com human mammary epithelial cells. (A) Decreases in
Syk protein levels are shown for control versus Syk siRNA transfection of normal MCF10A cells and tumorigenic MCF10AneoT and DCIS.com cells.
Increased cell proliferation (B) and cell growth (C) was observed following Syk knockdown. (D) Increased velocity of MCF10A, MCF10AneoT, and
DCIS.com cell migration was observed in Syk knockdown cells using a scratch/wound assay. (B–D) Data is represented as means +/2 SEM. P values
are significant by the student’s t-test for all cell lines, average of 3 independent experiments.
doi:10.1371/journal.pone.0007445.g001
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epithelial cells as well as in tumor-forming cell lines.
Effects of Syk knockdown on invasion and branching in
3D matrices. To determine whether loss of Syk in normal
breast epithelial cells would lead to acquisition of an invasive
phenotype in 3D Matrigel, we cultured cells in Matrigel following
siRNA knockdown. After 48 hours of culture, MCF10A cells
treated with control siRNA formed small round cell aggregates
whereas Syk siRNA dramatically increased the size of the colonies
which took on an irregular shape similar to initial stages of in vitro
branching (Figure 2A). The effect was not as dramatic in the
MCF10AneoT and DCIS.com cells, but in all three cell lines, the
differences were statistically significant (Figure 2A).
Similarly, we determined the morphology of the epithelial cells in
3.0 mg/ml bovine collagen I gels, a setting that is more closely akin
to the stromal cell environment. Following Syk knockdown,
MCF10A cells took on a more fibroblast-like morphology in
collagen, extending more cellular protrusions (Figure 2B). Cells
became significantly less round in shape as shown in the
representative phalloidin-stained cells and as quantified by cell
shape (Figure 2B). Cell migration on the collagen I gels was
significantly enhanced by siRNA targeting Syk compared with
control siRNA (Figure 2C). siRNA knockdown experiments, in
summary, have demonstrated that loss of Syk significantly enhances
cell proliferation, migration, and invasive morphologies in normal
and transformed breast epithelial cells alike, and the changes in
migration and invasion can be observed in assays on plastic, or in
3D matrix settings such as Matrigel or collagen I mats.
Loss of Syk increases tumorigenic and metastatic
potential. Soft agar assay and chemoinvasion assays through
Matrigel in Boydon chambers are more accurate predictors of
increased metastatic potential. Therefore, we created shRNA
knockdown cell lines for MCF10A, MCF10AneoT, and
DCIS.com to obtain stably transfected cells for use in longer
term experiments (Figure 3A). Similar to siRNA knockdown of
Syk, shRNA knockdown enhanced cell proliferation by 2–3 fold in
each of the cell lines measured by the MTS assay (Figure 3B). In
Boydon chamber chemoinvasion assays, both siRNA and shRNA
Syk were effective in substantially increasing chemoinvasion
(Figure 3C). Similarly, loss of Syk in shRNA stably-expressing
cell lines was associated with significantly enhanced colony growth
within soft agar (Figures 3D and S2). We conclude from this series
of experiments, that Syk loss results in increased chemoinvasion
and enhanced colony formation in normal and transformed
human mammary epithelial cells.
Syk knockdown gene expression changes in MCF10A cells
related to epithelial-to-mesenchymal transition (EMT),
growth factor and stress pathways, and invadopodia
formation. To explore the mechanisms whereby loss of Syk
promotes invasion, microarray analysis was performed on
MCF10A cells transiently transfected with control or Syk siRNA
and cultured on a mat of collagen I. After Syk knockdown and
culture on collagen, the phenotype of cells does become less
epithelial and more mesenchymal (Figure 2) as indicated by loss of
keratin genes (Keratin 6B, 10, 23), genes associated with stratified
epithelium (small proline-rich protein 1A, involucrin, sciellin) and
luminal mammary epithelium (CD24), the extracellular matrix
(CD36, the thrombospondin receptor) and gain of genes related to
integrin/ECM signaling (integrin beta 5, integrin-linked kinase,
laminin gamma 1), collagen biosynthesis and crosslinking (lysyl
oxidase (LOX), lysyl oxidase-like 2 (ENTPD4), procollagen-lysine,
2-oxoglutarate 5-dioxygenase 2 (PLOD2), procollagen-proline, 2-
oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha
polypeptide I (P4HA1)), and growth factor signaling (EGFR,
VEGF, TGFb1) (Table S1). This suggests that Syk loss releases
inhibition of signaling pathways that are normally repressed in
epithelial cells and that promote increased proliferation, motility,
and invasiveness. Consistent with the changes in phenotype that
we observed, i.e., following epithelial-to-mesenchymal transition
(EMT), we found that vimentin protein expression was
dramatically increased following Syk siRNA knockdown in
MCF10A, MCF10AneoT, and DCIS.COM (Figure 4A).
To assess overall gene expression changes due to Syk loss in
more detail, we performed an Ingenuity Pathway analysis using as
input all of the genes that were differentially expressed on collagen
following Syk knockdown. The analysis resulted in the identifica-
tion of a number of networks and their interactions (Table S2).
Several of these networks were linked and identified differentially
expressed genes related to EMT and Syk signaling including
EGFR, TGFb1, and NFkB networks (Figure S3 and Table S2).
These interactive networks are summarized in Figure S4 with
‘‘hubs’’ that include EGFR, TGFb1, NFkB, integrin, collagen, and
Rac. Therefore, microarray analysis supports the role of these
pathways and their contribution to the changes in phenotype and
behavior induced following Syk loss.
Invadopodia-related gene expression. Using the same
microarray data, we asked whether expression of invadopodia-
related genes was enhanced in MCF10A Syk knockdown cells
cultured on collagen. We prepared a list of proteins (total 63, 117
probe sets) required for localized matrix degradation, a functional
identifier of the presence of invadopodia [15] and determined that
a subset were differentially expressed following Syk knockdown
and culture on collagen. CORO1A, WASL, GRB2, and PLAUR
were down regulated and ITGB1, PAK1, MAPK7, LAMP1,
WASF1, VEGFA, ADAM12, and TGFb1 were up regulated
(Table S3). The multilayered relationships connecting the gene
networks differentially regulated by Syk identified in Figures S1
and S2 and the invadopodia gene network (data not shown) are
shown in Figure S1 (blue lines).
Since the epidermal growth factor receptor (EGFR) mRNA was
up-regulated (Table S1), but did not appear on the invadopodia
network (not shown), we validated up regulation of EGFR at the
protein level. We found that EGFR levels increased markedly in
the MCF10AneoT (ras-transformed) cells (Figures 4B and S5A).
Phosphorylation of Y1045 EGFR was up regulated slightly (less
than 2 fold) in both Syk siRNA and Syk shRNA knockdown cells
on collagen in each of the cell lines (Figures 4B and S5A).
Functional invadopodia. To determine whether invadopodia
formation is linked to EMT and increased cellular invasion, we asked
whether invadopodia were induced or increased following Syk loss.
Since MMP14 is required for invadopodia-mediated matrix
degradation and invasion on both collagen and gelatin [16,17], we
first measured MMP 14 (MT1-MMP) using flow cytometry (FACS).
Cell surface expression was dramatically increased following Syk
knockdown in cells cultured on plastic (Figure 4C).
Next, we performed a localized degradation assay to measure
invadopodia activity by culturing cells on fluorescent, crosslinked
films [18]. Evidence that cells underwent EMT was further
obtained by immuno-staining cell monolayers with phalloidin to
detect F-actin and cortactin (Figure 4D) in cells seeded on
fluorescent crosslinked gelatin to detect invadopodia, or F-actin,
cortactin, and vimentin (Figure 4E). We found in cells seeded at
confluent density that control siRNA-treated cells were cobble-
stone in appearance and polarized and the cell-cell borders were
delineated by adjacent rings of actin filaments (Figures 4D, E, and
S5B, con siRNA). In contrast, the Syk siRNA-treated cells were
disorganized in appearance with regions of fibroblast-like cell
spreading (Figures 4D, E and S5B, Syk siRNA).
Syk Loss in Breast Cells
PLoS ONE | www.plosone.org 3 October 2009 | Volume 4 | Issue 10 | e7445Figure 2. siRNA knockdown of Syk increases motility and invasive cell morphology in three dimensional cultures. (A) Cells were
transfected with control or Syk siRNA and cultured in Matrigel for 48 hours. MCF10A colony size was the most dramatically influenced by Syk
knockdown. Scale bars correspond to 200 mm. (B) Cells were seeded at sub-confluent densities on top of bovine collagen I gels (3.0 mg/ml), cultured
5 or 20 hours, fixed and stained with AlexaFluor488-phalloidin. Images of cells cultured for 20 h are shown. Scale bars are 50 mm (at left) and 5 mmi n
the higher magnification views at right. The invasive phenotype was quantified by measuring shape factor. A shape factor of 1 is equivalent to a
circle. (C) In a separate experiment, the velocity of cell migration on collagen I was determined. Scale bars are 10 mm. (A–C) P values are significant
by the student’s t-test for all three cell lines. Data are represented as mean +/2 SEM.
doi:10.1371/journal.pone.0007445.g002
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matrixwasquantified.SyksiRNAknockdownfollowedbyplatingat
non-confluent (40–45%) conditions elevated hole formation 5.6 fold
overthe control siRNA-treated cells,whereasat confluent (90–95%)
conditions, Syk siRNA knockdown elevated hole formation 5.9 fold
over the control cells (Figures 4D and F). Thus, loss of Syk increased
invadopodia-mediated matrix degradation.
Invadopodia formation and vimentin expression are correlated
with Syk negativity in breast cancer cells [19–21]. To determine the
relationship between vimentin expression and the ability to form
invadopodia, we stained cells with anti-vimentin antibody, phalloi-
din, and DAPI (Figure 4E). 34% of cells cultured at sub-confluent
density on gelatin films contained vimentin-positive filaments and
the percentage of vimentin-positive cells increased to 48% after Syk
knockdown (Figure 4G, Non-confluent). The percentage of
vimentin-positive cells increased from 11% to 27% after Syk
knockdown in confluent cells (Figure 4G, Confluent). Examining
individualcellsand thesubtendingmatrix,wedeterminedthat there
was no correlation between cells that expressed vimentin filaments
and those that formed invadopodia since 43% of Syk knockdown
cells forming holes were vimentin filament-positive and the
remaining cells were vimentin filament-negative.
Overlap of invadopodia and breast cancer stem cell
markers. Participation of CD44 (hyaluronan receptor) and
CD49f (a6 integrin) in invadopodia (tumor cells) or podosomes
(immune cells) has been previously reported [22–24]. We asked
whether the cell surface expression of CD44 or CD49f was altered
in MCF10A following Syk knockdown in concert with CD24
expression changes. CD24 is a luminal epithelial marker, and is
used as a breast cancer stem cell marker in combination with other
stem/progenitor cell markers such as CD49f (integrin alpha6) and
CD44 [25–27]. FACS co-staining analysis of CD44/CD24 and
CD49f/CD24 revealed that CD44 and CD49f were dramatically
enhanced at the cell surface, whereas CD24 was modestly
suppressed or unaffected (Figures 4H and S5C).
In vivo studies
Syk loss increases ductal branching and proliferation in
the Syk
+/2 mouse mammary gland. To determine the effect
of Syk loss during normal mammary gland development in vivo,w e
examined Syk hetero-knockout (Syk
+/2) mice (129 background)
[12]. Homozygous Syk knockout mice are not viable, with most
mice dying at approximately 16.5 days of gestation [12]. At 10 and
12 weeks of age, mammary glands from virgin Syk
+/2 female
mice showed increased ductal branches and alveolar development
compared with Syk
+/+ mice in the 4rth inguinal gland as shown in
the whole mount analysis (Figures S6A–C). As expected, Syk
protein expression was strongly decreased in mammary gland and
spleen from virgin Syk
+/2 female mice compared with those
tissues of wild type (WT) female mice (129 back ground) (Figure
S6D). These data suggest that Syk loss might enhance ductal
development in mammary gland.
Syk
+/2 (FVB) mammary glands show strongly enhanced
branching morphogenesis. The Syk
+/2 mice (129
background) were crossed with eGFP
+/+ mice (FVB background)
and loss of Syk expression in heterozygote female mammary glands
was confirmed (Figure 5A). Using immunohistochemistry, Syk
expression was strongly detected in mammary glands of WT female
mice where it localized to luminal epithelium and mammary gland
lymph nodes in subsets of lymphocytes (Figure S5A, Syk
+/+)a n di n
thespleen(notshown).Atthosesame sites,Sykwasdecreased inSyk
+/2 mice (Figure S7A, Syk
+/2).
To examine the morphology of ductal development during
puberty, whole mount analysis was performed on Syk
+/2 and WT
Figure 3. siRNA and shRNA knockdown of Syk enhances
chemoinvasion and anchorage independent proliferation. (A)
MCF10A, MCF10AneoT, and DCIS.com cells were transduced with Syk or
control shRNA in a lentiviral vector. Western blot analysis of puromycin-
selected cell populations is shown. (B) The MTS proliferation assay
revealed that shRNA cell lines behave similarly to the siRNA transiently
transfected cells with respect to Syk knockdown; cell proliferation was
enhanced. (C) Chemoinvasion assays were performed in parallel using
cells transiently transfected with control or Syk siRNA or stably
transduced with lentiviral control or Syk shRNA. Loss of Syk increases
chemoinvasion in every case. (D). In soft agar assays, each of the Syk
shRNA knockdown cell lines experienced increased colony formation.
Representative images are shown in Figure S3. (B–D) Data are
represented as means +/2 SEM. P values are significant by the
student’s t-test for each cell line.
doi:10.1371/journal.pone.0007445.g003
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PLoS ONE | www.plosone.org 5 October 2009 | Volume 4 | Issue 10 | e7445Figure 4. Syk knockdown MCF10A cells express EMT marker, invadopodia, and stem/progenitor marker proteins, and
invadopodia. (A) Cell extracts from cells cultured on plastic were blotted with anti-vimentin antibodies and then re-probed with anti-a-actin
antibodies. Vimentin protein was up-regulated following Syk knockdown. (B) Cell extracts were also probed for anti-pY
1045-EGFR, and then re-probed
for anti-EGFR and anti-a-actin. Overall, activated EGFR was up-regulated by Syk knockdown in MCF10 and DCIS.com, but not markedly in
MCF10AneoT. The top most blot is a shorter exposure than the one below it. Results for shRNA are shown in Figure S5A. (C) Flow cytometry was used
to measure cell surface MMP14 staining of control versus Syk siRNA knockdown in MCF10A. Three experiments were averaged. BT549 breast cancer
cells were used as positive control for cell surface MT1-MMP (mean 420.8). (D) Images from the gelatin-degradation assay for invadopodia from
MCF10A cells from three color confocal imaging (phalloidin, green; cortactin, blue; gelatin, magenta). Holes are formed in the gelatin matrix (gel)
following Syk siRNA knockdown. Scale bars =20 mm. A higher magnification view of the area within the red boxes is shown in Figure S5B. (E) Three
color confocal images were taken of cells cultured on crosslinked gelatin showing the distribution of DAPI (nuclei, blue), phalloidin (F-act, green), and
vimentin (magenta) in control versus Syk siRNA transfected MCF10A cells. Scale bars =20 mm. (F) Invadopodia activity was upregulated in Syk siRNA
transfected MCF10A. (G) Number of vimentin positive cells was increased in Syk siRNA transfected MCF10A cells in non-confluent and confluent
cultures. (H) Results for two color flow cytometry from three experiments each for cell surface CD44/CD24 and CD49f/CD24 demonstrate significant
elevation in CD44 and CD49f at the cell surface following Syk knockdown by siRNA in MCF10A cells.
doi:10.1371/journal.pone.0007445.g004
Syk Loss in Breast Cells
PLoS ONE | www.plosone.org 6 October 2009 | Volume 4 | Issue 10 | e7445female mammary glands at different ages. In strong agreement
with the evident change in morphology of Syk
+/2 mice on a 129
background, mammary glands from virgin Syk
+/2 female mice
displayed more abundant ductal branches and end buds compared
with the wild type glands as shown in the whole mount analysis at
3, 6, 8, 10, 12 weeks and pregnancy (EP, early pregnancy, E6.5
and LP, late pregnancy, E16.5) (Figures 5B and 5C). Next, we
found that the distance from lymph node to TEB in the mammary
gland was significantly increased in the Syk
+/2 mice compared to
that of WT mice during pre-puberty (3 weeks), puberty (6 and 8
weeks) as well as in late pregnancy glands (Figure 5D). The
differences were not significant at other time points.
We next analyzed mammary gland morphology of pubertal and
multiparous mice to determine if Syklossaffects end bud morphology
or results inepithelialhyperplasia and abnormal ducts or end buds.In
10 week animals, the branches and end buds of Syk
+/2 mice formed
lumens similar to the wild type animals, although in the heterozygote
mammary glands, many more terminal ends formed along the length
and tips of the ducts (Figure S7B, X-Y, 10 wk). Similarly, glands from
late pregnancy (16.5) Syk
+/2 mice had many more lobules (Figure
S7B, X-Y, LP). The lobules, like those from the wild type pregnant
females, were hollow balls, however, the size and densityof formation
was significantly enhanced compared with wild type (Figure S7B, X-
Y view, LP).
Figure 5. Enhanced branching morphogenesis in mammary glands of Syk
+/2 mice. (A) Syk protein is decreased in mammary gland
extracts (minus the mammary gland lymph node) and spleen from 12-week virgin Syk
+/2 heterozygous compared with Syk
+/+ wild type females.
Spleen extracts were used as positive control. (B) The average number of buds were counted in mammary glands from Syk
+/+ wild type (black bars)
and Syk
+/2 heterozygous mice (gray bars) from 3-, 6-, 8-, 10-, 12-week virgin and early and late pregnancy females (EP and LP, respectively). P value
was significant by the student’s t-test for 6-, 8-, 10-, 12-week virgin females and early- and late-pregnancy females (n=3 animals per time point). In a
separate experiment, mammary glands from 10 additional wild type and 10 heterozygous knockout Syk mice were examined at 8 weeks confirming
the increase in bud formation after partial Syk loss (B, inset). Data are represented as means from three mice +/2 SEM except for B, inset, where
n=10 mice. (C) Representative images of mammary glands from Syk
+/+ wild type and Syk
+/2 heterozygote knockout mice. Scale bars correspond to
150 mm in all panels. (D) The mean distance was determined from lymph node to the distal end of ducts in mammary glands from Syk
+/+ wild type
(black bars) and Syk
+/2 heterozygous mice (gray bars) at 10-day and 3-,6-,8-,10, 12-week virgin and early and late pregnancy females (n=3 animals
per time point). P value is significant by the student’s t-test for 3-, 6-, 8-week virgin females and late-pregnancy females. Data are represented as
means +/2 SEM for three glands each.
doi:10.1371/journal.pone.0007445.g005
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mammary gland development is present in two different strains of
mice. Taken together, these data indicate that Syk is haploinsuffi-
cient and reduced levels can significantly impact murine
mammary gland development.
Increased proliferation and invasiveness of mouse
mammary epithelial cells in vivo and in vitro. Following
the observation of increased ductal development in Syk
+/2 mice,
we performed an assessment of cell proliferation in mammary
gland tissues to determine whether epithelial cells were more
proliferative after Syk loss. In both 10 and 12 week animals, the %
positive Ki67 nuclei were significantly and dramatically increased
in the heterozygote knockout Syk
+/2 virgin mice compared with
the wild type (Figures 6A and B).
Next, we isolated primary mouse epithelial cells to determine in
vitrotheirproliferativeandinvasivecapacity.Thepercentofprimary
epithelial cells isolated from mammary glands of the Syk
+/2 virgin
females in S-phase was 2.4 fold higher than wild type animals
(Figure 6C). We used a three-dimensional in vitro model consisting of
primary mammary epithelial cells embedded in a reconstituted
Figure 6. Heterozygous Syk knockout accelerates cell proliferation and invasiveness of mouse mammary epithelial cells. (A)
Representative images illustrate sections triple stained with anti-Ki67 (red), anti-keratin14 (CK14m green), and DAPI (blue) from mammary glands of
Syk
+/+ wild type and Syk
+/2 heterozygous mice from 12-week virgin females. Scale bars correspond to 30 mm. (B) Increased mammary epithelial cell
proliferation was quantified from images illustrated in (A) in three animals for each point. (C) Primary cell cultures also exhibit increased cell
proliferation. Total % of cells in S-phase was quantified in primary cells from Syk
+/+ wild type and Syk
+/2 heterozygous mice from 12-week virgin
females. (D) Freshly isolated primary mammary epithelial cells were embedded Matrigel. Organoids were imaged at 24 hrs and show greatly
enhanced size in Syk heterozygous knockdown compared with wild type glands. A typical invasive leading edge is indicated (arrow). Scale bars
correspond to 50 mm. Increased cellular area (E) and fiber length (F) of organoids was assessed using Metamorph Image software. In all cases (B–F),
data is represented by means +/2 SEM. P values are significant by the student’s t-test.
doi:10.1371/journal.pone.0007445.g006
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invasion. Epithelial cells extracted from mammary gland(s) of wild
type mice formed spherical ‘cysts’ without branches during the
course of 24 hour culture (Figure 6D). In contrast, cells isolated
from Syk
+/2 mice formed invasive, branching processes after 24 h
(Figures 6D, arrow and 6E, F). Thus, both proliferation and
invasion were enhanced in primary mouse epithelial cells in
heterozygote glands compared with wild type.
Mammary hyperplasia and tumor formation in
heterozygote animals. In order to determine whether aged
heterozygote animals develop tumors, five virgin Syk
+/2 mice and
virgin wild type mice were examined at one year. Whole mounts of
the fourth inguinal wild type mammary glands revealed limited
ductal structure in wild type glands, whereas those of the Syk
+/2
animals were densely filled with epithelial structure (Figure 7A).
Loci of hyperplasias were found in the mammary gland whole
mounts of the Syk
+/2 animals (Figures 7A and B). The epithelial
structures were clusters of lobules each containing a small central
lumen, whereas the hyperplasias contained densely packed solid
cores of irregularly shaped lobules (Figure 7B, X-Y views).
At one year, each of the five Syk
+/2 females had formed
mammary tumors associated with the 3
rd or 4
th inguinal glands
whereas none of the Syk
+/+ wild type females had formed them.
The tumors, one in each animal, were attached to the mammary
fat pad (not shown). The tumors were invasive, intraductal
carcinoma (IDC). A representative view of one of the tumors is
shown in Figure 7C. At one year, at least one animal has shown
the development of lung metastases.
Discussion
The progression cell line series of MCF10A, MCF10AneoT, and
DCIS.com exhibited a progressive loss of Syk. This result mirrors
thelossofSykobservedinbreasttissuesfrompatients[4].Strikingly,
knockdown of Syk using either siRNA or shRNA consistently
enhanced proliferation, motility, invasion, and anchorage-indepen-
dent growth in each of these cell lines along the progression series to
DCIS.com, a cell line modeling ductal carcinoma in situ (DCIS).
Thus, changes in levels of Syk potently mediate their effects on these
activitiesand suggestthatSykmustbepresentinepithelialcellsatall
stages of progression including benign tissues in order to suppress
invasive, tumor-like cell behavior. The results in human breast
epithelial cells are supported by the results in the mouse mammary
gland where loss of one allele had an impressive effect on mammary
ductal structure and ultimately on carcinoma development. In both
human and mouse epithelial cells, we demonstrated increased
cellular proliferation and invasion. The mouse heterozygote model
further demonstrates that partial systemic loss of Syk can result in
hyperplastic growth, tumorformation, and insomecases metastasis.
The results on Syk knockdown in MCF10A cells support the
interpretation that Syk is required in the epithelial cells of normal
mouse mammary glands to control proper growth and invasion
during puberty although it is possible that additional factors
contribute since Syk is present in other tissues including immune
cells and endothelium [1].
Multiple lines of evidence suggest that loss of Syk triggers EMT.
EMT-related phenotypic changes are evidenced by change in
cellular morphology and size in Matrigel and collagen I matrix. In
addition, vimentin expression was strongly up-regulated following
loss of Syk in the MCF10A cell lines. Vimentin loss is associated
with the invasive and mesenchymal phenotype observed following
EMT in multiple breast cancer cell types [19,28]. Our
observations of spontaneous EMT and vimentin upregulation in
subconfluent cultures of MCF10a are consistent with previous
Figure 7. Heterozygous Syk
+/2 mice develop mammary gland
hyperplasia and ductal carcinoma. (A) At one year in virgin
females, 4
th inguinal mammary glands reveal a denser epithelial
network in heterozygote compared to wild type glands. Insets at right
are higher magnification views of the distal ductal tree. An area of
hyperplasia in the heterozygote gland (Syk +/2) indicated by a red box
is enlarged. Scale bars correspond to 5 mm and 250 mm insets at right
and 1 mm inset below. (B) Multiphoton imaging of carmine red
autofluorescence in whole mounts of the Syk +/2 gland revealed that
the branching epithelium is over developed but lumens are visible (X-Y,
inset at left). The hyperplastic portion contains no lumens (X-Y, inset at
right). Scale bars correspond to 50 mm. (C) Hemotoxylin/eosin stained
paraffin section from an invasive ductal carcinoma taken from a one
year, virgin female Syk
+/2. Scale bar is 50 mm.
doi:10.1371/journal.pone.0007445.g007
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suppressed by Syk. Interestingly, although vimentin expression in
cell lines is correlated with their invasive capacity, vimentin
filament expression was not correlated with invadopodia forma-
tion and degradation in individual cells. This is consistent with the
report that although vimentin is associated with early sites of
formation of podosomes in smooth muscle and osteoclasts, it does
not seem to be directly involved in podosome formation and
vimentin does not localize at the puncta of actin [34,35]. Thus, a
more intensive study must be undertaken to determine the
molecular relationship between vimentin and invadopodia struc-
tures and cell motility and invasion.
Microarray analysis revealed that Syk regulates a large number of
genes in the TGFb1, NFkB, and EGFR pathways and that TGFb1
and VEGF are upregulated. These pathways constitute important
regulators of cell invasion. In particular, TGFb-mediated EMT
requires NF-kB [36]. MCF10CA1, a tumor forming cell line derived
from MCF10A, has been reported to form invadopodia and undergo
EMT in a process requiring PI3K and c-Src in response to TGFb1
[37,38]. Both PI3K and NF-kB are reported to be inhibited by Syk in
breast cancer cell lines [7] and they contribute to invadopodia
formation [15] directly or indirectly. And, EGFR activity is
downregulated by Syk as is the downstream kinase c-Src [4,8].
Thus,ourresultsrevealthatSykislikelytocontrolaTGFb1 signaling
pathway in addition to EGFR/NFkB and their interacting genes
(Figures S3–S4). Thus, Syk potentially regulates at least three major
signaling pathways to suppress proliferation and invasion. These
pathways have important functions in the development and
maintenance of the normal mammary gland and their disruption
gives rise to EMT, invadopodia formation, and cancer progression.
Consequently, the significance of the overlap between invadopodia-
related proteins and cell surface stem cell markers (CD44 and
CD49F) is not known but is highly suggestive of the involvement of
invadopodia cell surface proteins in stem/progenitor cell function
during development.
In conclusion, the present study demonstrates for the first time that
t h ep r e s e n c eo fw i l dt y p el e v e l so fS y ki nn o r m a lb r e a s te p i t h e l i a lc e l l s
is critical to suppress proliferation and invasion, and that partial loss
promotes hyperplasia and the eventual formation of mammary
tumors in vivo. The significanceof oral or locallyapplied Syk inhibitors
forbreastcancerriskisofcriticalconcerninthecontextofthecurrent
development of agents targeting Syk for therapeutic treatment of
allergy, asthma and autoimmune disease [39,40].
Materials and Methods
Mice
Ethics Statement. All animals were handled in strict
accordance with good animal practice as defined by the Georgetown
University Care and Use of Animals Committee (GUGUAC, protocol
no. 07–020) and by the Association for the Assessment and
Accreditation of Laboratory Animal Care (AAALAC).
Syk heterozygous (+/2) 129 background mice [41] were
crossed with homozygous eGFP
+/+ (Enhanced Green Fluorescent
Protein) transgenic FVB mice and the progeny genotyped for Syk.
eGFP mice were purchased from Jackson Laboratory (Bar Harbor,
Maine). Syk
+/2/eGFP
+/+ were back crossed six times with
homozygous eGFP
+/+ mice. Homozygous eGFP
+/+ mice were
selected based on fluorescence intensity. These mice were
genotyped for Syk and the Syk
+/2/eGFP
+/+ (referred to as Syk
+/2) were used for this study. Genotypes of the mice were
confirmed by PCR analysis using the oligomers 59-AGA GAA
GCC CTG CCC ATG GAC-39,5 9-CCT TGG GAA AAG CGC
CTC CCC TAC CC -39 and 59-GTC CAG GTA GAC CTC
TTT GGG C-39. Methods for microscopic analysis of mammary
gland morphologies are found in Supplementary File S1.
Cell culture. MCF10A [42], MCF10AneoT [43], and
MCF10DCIS.com [44] cell lines were acquired from Barbara
Ann Karmanos Cancer Institute (obtained at passage number 174,
49, 30, respectively), passaged upon approaching confluence using
standard techniques and were maintained in complete media
(DMEM/F12 (50:50 mix) supplemented with 5% horse serum,
10 mM HEPES, 10 mg/ml insulin, 20 ng/ml epidermal growth
factor, 0.5 mg/ml hydrocortisone, 100 ng/ml cholera toxin).
Details and minor modifications of the methods for culture of
cells on collagen I matrices, Matrigel, soft agar, and primary
culture of mouse mammary epithelial cells and the assays used to
quantify proliferation, migration, invasion, and morphologies are
found in the Supplementary File S1 section.
Microarray Analysis. Global gene expression profiles were
measured using Affymetrix U133A 2.0 microarrays (with 22,283
probe sets) in MCF10A cell lines (control and Syk siRNA
knockdown cells on collagen gels or plastic). Total RNA was
extracted from cells seeded on collagen or plastic, using standard
TRIZOL-based techniques. Fragmented cRNA was prepared as
described in the Affymetrix Genechip Expression Analysis
Technical Manual. Hybridization, washing, and imaging steps
were performed in the Lombardi Comprehensive Cancer Center
Macromolecular Shared Resource. Raw images were pre-processed
using Microarray Suite 5.0 software (Affymetrix, Santa Clara, CA).
For the preprocessing of the microarray data, we used SemiRMA
[45] for background adjustment, loess for normalization and
median polish for summarization. The preprocessed data (log-
intensities) were then analyzed using a two-way ANOVA model
with interaction to assess differential gene expression. The two
factors are indicators for collagen coated dish (versus plastic dish)
and Syk siRNA (versus empty vector). Due to the small number of
replicates (3), we used empirical Bayes approach to borrow
information across genes [46]. The method of Benjamini-
Hochberg [47] was used to control FDR at 5%. Bioconductor
packages ‘‘affy’’ and ‘‘limma’’ were used in the analysis. All data is
MIAME compliant. Microarray data reported herein have been
deposited at the NCBI Gene Expression Omnibus (http://www.
ncbi.nlm.nih.gov/geo/) with the accession number GSE16200.
Other statistical analysis. Results are shown as the mean 6
standard error of the mean (S.E.M.). Statistical significance was
calculated by using the Student’s t-test and P,0.05 was accepted
as a significant value.
Supporting Information
File S1 Additional material and methods.
Found at: doi:10.1371/journal.pone.0007445.s001 (0.09 MB
DOC)
Table S1 Gene probes differentially regulated following Syk
knockdown in MCF10A cells cultured on collagen. MCF10A cells
cultured on collagen were subjected to microarray analysis to
determine gene probe sets whose expression was differentially
regulated following Syk knockdown. 1136 probe sets were
significantly up- or down-regulated at the FDR level of 0.05 as
described in Materials and Methods.
Found at: doi:10.1371/journal.pone.0007445.s002 (0.18 MB
PDF)
Table S2 List of gene probe sets from merged networks 1, 2, and
10. Gene probe sets that were differentially regulated following
Syk knockdown of MCF10A cells cultured on collagen (Supple-
mentary Table 1) were submitted to Ingenuity for analysis.
Syk Loss in Breast Cells
PLoS ONE | www.plosone.org 10 October 2009 | Volume 4 | Issue 10 | e7445Networks 1, 2 and 10 identified by analysis with Ingenuity were
merged and the gene probes listed here. The majority of entries
were represented by gene probe sets whose expression was
differentially regulated following Syk knockdown of MCF10A
cells cultured on collagen as indicated.
Found at: doi:10.1371/journal.pone.0007445.s003 (0.01 MB
PDF)
Table S3 Invadopodia gene probes that were differentially
regulated following Syk knockdown in cells cultured on collagen.
139 gene probes were linked with 63 invadopodia-related proteins
(proteins whose role in invadopodia function was determined by
the criteria of matrix degradation on gelatin crosslinked films or
localization of MT1-MMP at invadopodia [1]). Levels of 17 gene
probes were significantly changed at the FDR level of 0.05 as
described in Materials and Methods.
Found at: doi:10.1371/journal.pone.0007445.s004 (0.01 MB
PDF)
Figure S1 Time course of scrape/wound closure for MCF10A,
MCF10AneoT, and DCIS.com human mammary epithelial cells.
A scratch wound was made and the degree of closure achieved
over 24-hr incubation was imaged by time lapse microscopy and
measured using Metamorph Image Analysis software. Graphs and
representative images from cell lines MCF10A (A), MCF10AneoT
(B), and DCIS.com (C) are shown at 0 hr and 16 hrs. Scale bars
correspond to 75 mm in all panels.
Found at: doi:10.1371/journal.pone.0007445.s005 (1.06 MB TIF)
Figure S2 Soft agar growth assays. In soft agar assays, each of the
Syk shRNA knockdown cell lines experienced increased colony
formation. Representative images are shown. Scale bars are all 30 mm.
Found at: doi:10.1371/journal.pone.0007445.s006 (0.40 MB TIF)
Figure S3 Detailed map of three merged networks. Cells cultured
on collagen were analyzed to determine up- or down-regulated gene
probes following Syk knockdown. TGFb1, NFkB, and EGFR
constitute major ‘‘hubs’’ of three networks (networks 1, 2 and 10)
identified by Ingenuity (Supplementary Table 2). The links between
these three networks are shown in yellow. The intersection of the
invadopodia network (not shown) with the EGFR-NFkB-TGFb1
linked networks is indicated by dashed blue lines. Probe sets up-
regulatedareshowninred,thosedown-regulatedareshowningreen.
Found at: doi:10.1371/journal.pone.0007445.s007 (0.98 MB TIF)
Figure S4 Summary of major nodes in three networks. A
summary of the major nodes of interest in networks 1, 2, and 10
are shown, taken from Supplementary Figure 1. Orange lines
indicate interactions among the networks.
Found at: doi:10.1371/journal.pone.0007445.s008 (0.37 MB TIF)
Figure S5 EGFR, invadopodia, and cellsurface invadopodia/stem
cell markers. (A) Extracts of MCF10A, MCF10AneoT, and
DCIS.com transfected with control or Syk siRNA were probed for
anti-pY1045-EGFR, and then stripped and re-probed for anti-EGFR
and then again for anti-a-actin. Overall, activated EGFR was up-
regulated by Syk knockdown. The last two lanes are two different
loadings of EGF-treated MCF10A positive control cell lysates. (B)
Images from the gelatin-degradation assay for invadopodia from
MCF10A cells from three color confocal imaging (phalloidin, green;
cortactin, blue; gelatin, magenta). Higher magnification images
selected are shown here and indicated in Fig. 4D by the box. Scale
bars =10 mm. (C). Two color flow cytometry for CD44/CD24
(CD44) and CD49f (a6 integrin)/CD24 (CD49f) demonstrates
increased cell surface CD44 and CD49f with unchanged or slightly
decreased cellsurfaceCD24 followingSykknockdownbysiRNAand
culture of MCF10A cells on plastic.
Found at: doi:10.1371/journal.pone.0007445.s009 (2.17 MB TIF)
Figure S6 Enhanced branching morphogenesis in mammary
glands of Syk +/2 mice (129 background). (A) Mammary gland
branching and end buds are more prominent in Syk +/2
heterozygote. Scale bars correspond to 150 mm in all panels. The
average number of total tube area (B) and buds (C) were counted in
mammaryglandsfrom Syk+/+wildtype and Syk +/2heterozygous
mice. (D) Syk protein is decreased in Western blots of mammary
glands extracts (minus the mammary gland lymph node) and spleen
from 12-week virgin Syk +/2 heterozygous compared with Syk +/+
wild type females. Spleen extracts were used as positive control.
Found at: doi:10.1371/journal.pone.0007445.s010 (0.83 MB TIF)
Figure S7 Enhanced branching morphogenesis in mammary
glands of Syk +/2 mice. (A) Immunohistochemistry staining using
N-19rabbitpolyclonalanti-Sykantibodywasperformedonparaffin
sections of mammary glands from 10 week females. Decreased
expression of Syk protein is observed in mammary epithelial cells in
Syk +/2 heterozygous versus Syk +/+ wild type mice. Mammary
gland lymph nodes (LN) serve as internal controls where Syk is
expressed in different subpopulations of lymphocytes. Adjacent
ducts are indicated by arrows. Higher magnification views of end
buds are shown below, illustrating positively stained luminal
epithelium. Images were taken using identical microscope settings
for comparison. In the lower panel, scale bars correspond to 10 mm
and in their higher magnification insets to 30 mm. (B) Mammary
glands from Syk +/+ wild type and Syk +/2 heterozygote knockout
mice of 10 week (10 wk) virgin females and late pregnancy (LP)
females were dissected out and stained with carmine red in whole
mounts. Mammary gland branching and end buds are more
prominent in Syk +/2 heterozygote as illustrated in these
micrographs. Scale bars correspond to 150 mm in all panels.
Found at: doi:10.1371/journal.pone.0007445.s011 (4.42 MB TIF)
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